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Accurate prognostic information is desirable when counselling patients with brain metastases regarding their therapeutic options
and life expectancy. Based on previous studies, we selected serum lactate dehydrogenase (LDH) as a promising factor on which
we perform a pilot study investigating methodological aspects of biomarker studies in patients with brain metastases, before
embarking on large-scale studies that will look at a larger number of candidate markers in an expanded patient cohort. For this
retrospective analysis, 100 patients with available information on LDH treated with palliative whole-brain radiotherapy were
selected. A comprehensive evaluation of diﬀerent LDH-based variables was performed in uni- and multivariate tests. Probably,
the most intriguing ﬁnding was that LDH kinetics might be more important, or at least complement, information obtained from
a single measurement immediately before radiotherapy. LDH and performance status outperformed several other variables that
are part of prognostic models such as recursive partitioning analyses classes and graded prognostic assessment score. LDH kinetics
might reﬂect disease behaviour in extracranial metastatic and primary sites without need for comprehensive imaging studies and
is a quite inexpensive diagnostic test. Based on these encouraging results, conﬁrmatory studies in a larger cohort of patients are
warranted.
1.Introduction
During the last two decades, various research groups have
tried to improve our ability to predict overall survival of
patients with brain metastases from solid tumours. They
have identiﬁed a series of independent prognostic factors
for survival and, based on these, developed prognostic
scores [1–6]. Especially the scores developed on the basis
of studies performed by the Radiation Therapy Oncology
G r o u p( R T OG )h a v ega i n e dwi d e s p r e a da c c e p t a n c ea n dw e r e
validated by several groups, as recently summarised [7].
These scores named recursive partitioning analysis (RPA)
classes [2] and graded prognostic assessment (GPA) [1]b o t h
include Karnofsky performance status (KPS), age, and pres-
ence of extracranial metastases. Moreover, primary tumour
control is included in the RPA classes and number of
brain metastases in the GPA score. Despite their clinical
usefulness, these scores are not perfect in predicting survival.
As demonstrated in a recent analysis [8], even if one
combines information from several scores, some patients
with predicted short survival might do much better than
anticipated while other patients with predicted favourable
prognosis might die shortly after treatment.
While factors such as age are straight forward and easy
to assign, others are much more complicated and disputable.
For example, the term “presence of extracranial metastases”2 The Scientiﬁc World Journal
covers a broad spectrum ranging from just one or two small,
asymptomatic lung nodules to massive involvement of the
liver, possibly with additional lesions in the adrenal glands,
bones, and so forth. By just assigning “metastases present”
or“absent” potentially valuableinformation ontotaltumour
load, organ function, and clinical signiﬁcance is lost. Exten-
sive imaging and restaging on the other hand might not
always be indicated, for example, because no change in
immediate patient management is expected and/or resources
are limited. Therefore, surrogate markers of tumour load,
for example, serum biomarkers are an attractive area of
research. Our group has recently shown that serum lactate
dehydrogenase (LDH) is an important predictor of survival
in patients with brain metastases from malignant melanoma
[9]. LDH has also been included in a previous analysis that
conﬁrmed its independent prognostic impact [10]. More-
over, it inﬂuences the malignant melanoma staging system
(M1a and M1b require normal LDH). In patients with brain
metastases from lung cancer, the prognostic impact of LDH
has also been acknowledged [11, 12]. Furthermore, LDH
contributes to prognostic models in malignancies such as
renal cell cancer, germ cell tumours, and non-Hodgkin’s
lymphomas. We have therefore decided to select LDH as
a promising factor on which we perform a pilot study
investigating methodological aspects of biomarker studies in
patients with brain metastases, before embarking on large-
scale studies that will look at a larger number of candidate
m a r k e r si na ne x p a n d e dp a t i e n tc o h o r t .
2.MaterialandMethods
We analyzed patients from a previously described brain
metastases database, which is maintained and updated at
the ﬁrst author’s institution [8, 9]. For this retrospective
pilot study, 100 patients with available information on LDH
treated with palliative whole-brain radiotherapy (WBRT;
total dose 30Gy in 10 fractions; no surgery or radiosurgery)
during the last 5 years were selected. A backward inclusion
was used starting with all patients treated in 2011. Patients
were entered on a year-by-year basis until the target group
size of 100 was reached. All patients were treated at two
diﬀerent institutions in northern Norway. LDH was part
of routine blood chemistry and imaging assessment in
patients with newly detected brain metastases treated in
these institutions. LDH measurement no older than 2 weeks
before the ﬁrst fraction of WBRT was required. Elevated
LDH was deﬁned as ≥205 U/l according to the hospitals’
reference value. The prognostic impact of LDH was tested
in various fashions (comparison of normal versus elevated
LDH; normal versus 1.5x upper limit of normal (ULN) as
cut-oﬀ; by quartiles and by kinetics) in univariate analyses
(log-rank test). Actuarial survival was calculated with the
Kaplan-Meier method and compared between diﬀerent
groups with the log-rank test. For multivariate analysis of
survival Cox regression analysis was used. A P value ≤ 0.05
was considered statistically signiﬁcant. Sixteen patients were
alive at last follow-up (June 01, 2011) with a median follow-
up of 8 months (range 1–42). The patient characteristics are
shown in Table 1.
Table 1: Pretreatment characteristics of all 100 patients included in
this study.
Parameter Number and %
Elevated serum lactate dehydrogenase
(LDH) 59
Normal LDH 41
Extracranial metastases absent 14
Extracranial metastases present 86
Controlled primary tumour 71
Uncontrolled primary tumour 29
Solitary brain metastasis 17
Two or three brain metastases 44
More than 3 brain metastases 39
Female sex 70
Male sex 30
Lung cancer 36
Breast cancer 34
Gastrointestinal cancer 11
Malignant melanoma 10
Kidney cancer 4
Other primary cancer 5
Median Karnofsky performance status 70% (range 30–100)
Median age 62 years (24–85)
Median number of brain metastases 3 (1–50)
Median LDH 228 (99–3190)
3. Results
3.1. Univariate Analyses. Patients with normal LDH (<205
U/l)hadsigniﬁcantlylongersurvival(median4.0months)as
compared to those with elevated LDH (median 3.1 months),
P = 0.037 (Figure 1). With a diﬀerent cut-oﬀ (1.5x ULN,
i.e., LDH <307 U/l), a P value of 0.013 was found (median
survival 3.0 versus 4.0 months), (Figure 2). When evaluated
byquartiles,mediansurvivalwas5.5monthsinpatientswith
thelowestLDH,3.4monthsinthosewithintermediateLDH,
and 2.8 months in those with the highest LDH, P = 0.017
(Figure 3). Given that the lowest P value was found when
discriminating between patients with LDH higher versus
lower 1.5x ULN, this cut-oﬀ was chosen for conﬁrmatory
analysesstratiﬁedbyprimarytumourtype.Consistenttrends
were seen for all primary tumour types despite low numbers
of patients. Regarding lung cancer, median survival was 3.1
months in patients with elevated LDH and 5.6 months in
others; P = 0.145. Regarding breast cancer, median survival
of 3.9 versus 9.0 months was found; P = 0.39. Regarding
gastrointestinal primary tumours, median survival was 0.9
versus 3.3 months; P = 0.215. For melanoma patients, these
ﬁgures were 1.1 versus 5.5 months; P = 0.02.
Data on LDH kinetics were available in 33 patients. We
compared the LDH level 2 months before WBRT to that
immediately before WBRT. In 20 cases, an increase of at least
10% during the 2 months time period was found. In the
remaining 13 cases LDH had been stable, slightly decreasingThe Scientiﬁc World Journal 3
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Figure 1: Kaplan-Meier curves for overall survival: normal LDH
(n = 41) versus elevated LDH (n = 59); P = 0.037.
or increasing <10%. Patients with LDH increase ≥10%
had signiﬁcantly shorter survival (median 2.3 months) as
compared to the remaining patients (median 13.5 months);
P = 0.001 (Figure 4).
3.2. Multivariate Analyses. All Cox regression analyses
included KPS (continuous variable), age (continuous vari-
able), number of brain metastases detected on magnetic
resonanceimagingscans(continuousvariable),andpresence
versus absence of extracranial metastases, that is, all param-
eters that determine the GPA classiﬁcation. When adding
LDH (continuous variable) to these 4 parameters, only KPS
(P = 0.0001) and LDH (P = 0.002) retained statistical
signiﬁcance. Comparable results were seen when LDH was
entered as categorical variable with cut-oﬀ 1.5x ULN. The P
values were 0.0001 for KPS and 0.001 for LDH, respectively.
When both LDH variables were included, only the one with
cut-oﬀ 1.5x ULN retained signiﬁcance (KPS P value 0.0001,
LDH by cut-oﬀ 1.5x ULN P value 0.019, LDH as continuous
variable P = 0.188).
The model based on LDH kinetics included only 33
patients, as mentioned previously. LDH was entered as
categoricalvariablewithcut-oﬀ≥10%increaseduringatime
period of 2 months. In addition, LDH by cut-oﬀ 1.5x ULN
wasincluded.Again,KPSwasthemostimportantprognostic
factor, P = 0.001, followed by LDH kinetics, P = 0.002,
and LDH by cut-oﬀ 1.5x ULN, P = 0.01. As in the previous
analyses, age, number of brain metastases, and extracranial
metastases were not signiﬁcant.
Inordertoexcludeanyconfoundinginﬂuenceofprimary
tumour control, which is included in the RPA scoring
system, these analyses were repeated with KPS (continu-
ous variable), age (continuous variable), number of brain
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Figure 2: Kaplan-Meier curves for overall survival: LDH less than
1.5x upper limit of normal (n = 65) versus LDH higher than 1.5x
upper limit of normal (n = 35); P = 0.013.
LDH highest quartile
LDH intermediate
LDH lowest quartile
0
25
50
75
100
0 61 2 1 8 2 4 30
Months from start of therapy
A
l
i
v
e
 
(
%
)
Figure 3: Kaplan-Meier curves for overall survival: LDH highest
quartile (n = 25) versus LDH lowest quartile (n = 25) versus
intermediate (n = 50); P = 0.017.4 The Scientiﬁc World Journal
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Figure 4: Kaplan-Meier curves for overall survival: LDH increase
≥10% within 2 months (n = 20) versus no such increase (n = 13);
P = 0.001.
metastases (continuous variable), presence versus absence of
extracranial metastases, and controlled versus uncontrolled
primary tumour. Again, KPS and LDH outperformed all
other variables and were the only ones to obtain statistical
signiﬁcance (details not shown).
4. Discussion
This pilot study, which was performed in a homogenously
treated patient population, is to the best of our knowledge
the ﬁrst one that included a comprehensive evaluation of dif-
ferent LDH-based variables. It represents a ﬁrst step towards
analyses of diﬀerent surrogate markers in larger patient
groups and conﬁrms that such studies are warranted because
biomarkers obviously might add important prognostic
information. Moreover, the present data provide important
insights,whichwillinﬂuencethedesignofourfuturestudies.
Probably, the most intriguing ﬁnding was that LDH kinetics
might be more important, or at least complement, informa-
tionobtainedfromasinglemeasurementimmediatelybefore
WBRT. Since the number of patients with available data on
LDH kinetics was limited, conﬁrmatory studies are needed.
A possible explanation for the impact of LDH kinetics is that
this parameter reﬂects disease progression in extracranial
sites, and that patients with well controlled or even absent
extracranial disease have longer survival. In general, LDH
is upregulated in many tumours and lactate enhances the
degree of tumour malignancy [13]. LDH level might also
increase with tumour volume. Compared to imaging studies,
LDH is an inexpensive diagnostic test. Lagerwaard et al.
[3] have analysed a much larger patient cohort with brain
metastases from diﬀerent primary tumours (n = 1292).
Apparently, their study is the largest one that included LDH
as a potential prognostic factor. Yet the only comparison
was made between patients with normal versus elevated
LDH (median survival 4 versus 2.2 months). Multivariate
analysis conﬁrmed that LDH inﬂuenced survival (risk ratio
1.55, 95% conﬁdence interval 1.32–1.81, P<0.001). A very
similar result was obtained in multivariate analysis of 692
patients with brain metastases from malignant melanoma
[14]. Again normal versus elevated LDH was included.
The hazard ratio was 1.6 (95% conﬁdence interval 1.3–2.0,
P = 0.00013). In terminally ill cancer patients referred for
palliative radiotherapy (with or without brain metastases,
diﬀerent primary tumour types), LDH was also associated
with survival outcome in multivariate analysis [15].
Our study was not powered to conﬁrm the independent
prognostic signiﬁcance of LDH in subgroups with diﬀerent
primary tumours. However, exploratory subgroup analyses
were all in agreement with the main analysis, which included
100 patients. While previous studies already suggested that
LDH predicts survival in patients with brain metastases from
malignant melanoma and lung cancer [9–12, 14], our data
suggest that LDH could also be useful in patients with breast
and gastrointestinal primaries. Future studies should address
whether LDH could replace other factors that are included
in the GPA score, for example, extracranial metastases, and
whether this would impact on the accuracy of survival
predictions.
Avoiding overtreatment in patients with poor prognosis
is crucial when trying to avoid unnecessary complications
and achieve maximum value for health care budget. The
challenge is to assign the right patient to the right treatment,
with clear objectives being set upfront, for example, pallia-
tion of symptoms in the terminal phase of disease. Robust
and reproducible prognostic models might guide clinical
decision making.
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